在PARP抑制剂治疗期间减轻T细胞DNA损伤可以提高抗瘤疗效
Jiahao Liu1,2, Xiaofei Jiao1,2, Wei Mu3
1Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Science translational medicine
|May 7, 2025
概括
聚 ((ADP-ribose) 聚合酶抑制剂 (PARPis) 损害T细胞,降低它们的有效性. 针对T细胞中的PARP1或工程PARPi耐受性CART细胞可以通过PARPis和免疫疗法提高癌症治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 聚分子酶抑制剂 (PARPis) 是标准的癌症疗法.
- PARPi 的有效性部分取决于T细胞的活性.
- PARPis可能会对T细胞产生负面影响,可能会限制它们的治疗效益.
研究的目的:
- 研究PARPi治疗对T细胞的影响.
- 确定PARPis影响T细胞的机制.
- 通过改善T细胞功能来探索增强PARPi疗效的策略.
主要方法:
- 来自新辅助尼拉帕里布试验的患者瘤样本的分析.
- 在体外和小鼠模型验证PARPi对T细胞的影响.
- 全基因组的CRISPR淘汰屏幕用于识别T细胞中的PARPi点.
- 工程 PARPi-耐受性 CAR T 细胞使用细胞因子基编辑.
主要成果:
- 在患者的T细胞中,PARPi治疗导致了DNA损伤,减少了增殖,增加了T细胞的亡.
- 确定PARP1是PARPi诱导的T细胞死亡的关键调解者.
- 在T细胞或工程CART细胞中对PARP1的基因修饰在临床前模型中提高了PARPi的疗效.
- 减少T细胞DNA损伤与改善的抗瘤反应相关.
结论:
- 在T细胞中PARPi诱导的DNA损伤是限制治疗疗效的关键因素.
- 针对T细胞中的PARP1或开发PARPi耐受性免疫细胞提供了一种有前途的策略,以增强PARPi疗法.
- 这些发现表明,有新的方法可以将PARPis与免疫疗法结合起来,以改善癌症治疗结果.
相关概念视频
DNA Damage can Stall the Cell Cycle
9.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Tumor Immunotherapy
401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401
Translesion DNA Polymerases
9.7K
Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
9.7K
Long-patch Base Excision Repair
6.9K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
6.9K


